Table 1 Baseline of patient characteristics
Characteristic | Radical surgery group | Standard surgery group | P value* |
|---|---|---|---|
Median age (range) | 56 years (35–82) | 56 years (26–79) | 1.000 |
FIGO stage | 0.045 | ||
Stage IIIC | 91(81.2 %) | 215(89.2 %) | |
Stage IV | 21(18.8 %)b | 26(10.8 %) | |
Primary tumor | 0.535 | ||
Epithelial ovarian cancer | 111 (99.1 %) | 240 (99.6 %) | |
Fallopian tube cancer | 1 (0.9 %) | 0 (0 %) | |
Primary peritoneal cancer | 0 (0 %) | 1 (0.4 %) | |
Histology | 0.084 | ||
Serous | 100(89.3 %) | 202(83.8 %) | |
Mucinous | 0(0 %) | 2(0.8 %) | |
Endometrioid | 2(1.8 %) | 2(0.8 %) | |
Clear cell | 2(1.8 %) | 5(2.1 %) | |
Others | 8(7.2 %) | 30(12.4 %) | |
Grade | 0.787 | ||
Grade1 | 0(0 %) | 2(0.8 %) | |
Grade 2 | 9(8.0 %) | 16(6.6 %) | |
Grade 3 | 102(91.1 %) | 218(90.5 %) | |
NA | 1(0.9 %) | 5(2.1 %) | |
ECOG performance status | 0.116 | ||
0 | 57(50.9 %) | 95(39.4 %) | |
1 | 49(43.8 %) | 126(52.3 %) | |
2 | 6(5.4 %) | 20(8.3 %) | |
ASA status | 0.358 | ||
1 | 59(52.7 %) | 107(44.4 %) | |
2 | 51(45.5 %) | 127(52.7 %) | |
3 | 2(1.8 %) | 7(2.9 %) | |
Preoperative serum CA125 | 0.245 | ||
Median serum level (range) | 1320 U/ml (67.2–77050) | 1725 U/ml (32.1–39145) | |
Neoadjuvant chemotherapy | 0.421 | ||
Yes | 20 (17.9 %) | 35 (14.5 %) | |
No | 92 (82.1 %) | 206 (85.5 %) | |
Ascites | 0.472 | ||
Median volume (range) | 1350 ml (0–7000) | 1500 ml (0–10000) | |
Bowel mesenteric carcinomatosis | 0.544 | ||
Yes | 78 (69.6 %) | 160 (66.4 %) | |
No | 34 (30.4 %) | 81 (33.6 %) | |
Residual disease in pelvis | <0.001 | ||
0 cm | 92(82.1 %) | 129(53.5 %) | |
0.1–0.5 cm | 15(13.4 %) | 71(29.5 %) | |
0.5–1 cm | 3(2.7 %) | 41(17.0 %) | |
>1 cm | 2(1.8 %) | 0(0 %) | |
Residual disease in middle abdomen | <0.001 | ||
0 cm | 60(53.6 %) | 69(28.6 %) | |
0.1–0.5 cm | 40(35.7 %) | 93(38.6 %) | |
0.5–1 cm | 9(8.0 %) | 79(32.8 %) | |
>1 cm | 3(2.7 %) | 0(0 %) | |
Total | 112 | 241 | |